IDEXX LABORATORIES INC (IDXX) Stock Fundamental Analysis
NASDAQ:IDXX • US45168D1046
630.73 USD
-4.17 (-0.66%)
At close: Feb 19, 2026
630.73 USD
0 (0%)
After Hours: 2/19/2026, 8:07:58 PM
Taking everything into account, IDXX scores 7 out of 10 in our fundamental rating. IDXX was compared to 185 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IDXX a very profitable company, without any liquidiy or solvency issues. IDXX has a decent growth rate and is not valued too expensively. These ratings could make IDXX a good candidate for quality investing.
1. Profitability
1.1 Basic Checks
- IDXX had positive earnings in the past year.
- In the past year IDXX had a positive cash flow from operations.
- Each year in the past 5 years IDXX has been profitable.
- IDXX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 30.34%, IDXX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 65.81%, IDXX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- With an excellent Return On Invested Capital value of 40.35%, IDXX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for IDXX is significantly above the industry average of 8.75%.
- The 3 year average ROIC (37.60%) for IDXX is below the current ROIC(40.35%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROIC | 40.35% |
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.6%
ROIC(5y)38.02%
1.3 Margins
- The Profit Margin of IDXX (24.65%) is better than 95.68% of its industry peers.
- In the last couple of years the Profit Margin of IDXX has grown nicely.
- IDXX's Operating Margin of 31.34% is amongst the best of the industry. IDXX outperforms 98.92% of its industry peers.
- IDXX's Operating Margin has improved in the last couple of years.
- IDXX has a better Gross Margin (61.72%) than 64.32% of its industry peers.
- In the last couple of years the Gross Margin of IDXX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% |
OM growth 3Y5.66%
OM growth 5Y4.24%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so IDXX is creating value.
- IDXX has less shares outstanding than it did 1 year ago.
- The number of shares outstanding for IDXX has been reduced compared to 5 years ago.
- The debt/assets ratio for IDXX has been reduced compared to a year ago.
2.2 Solvency
- IDXX has an Altman-Z score of 21.68. This indicates that IDXX is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of IDXX (21.68) is better than 96.22% of its industry peers.
- IDXX has a debt to FCF ratio of 1.04. This is a very positive value and a sign of high solvency as it would only need 1.04 years to pay back of all of its debts.
- IDXX has a better Debt to FCF ratio (1.04) than 90.27% of its industry peers.
- IDXX has a Debt/Equity ratio of 0.53. This is a neutral value indicating IDXX is somewhat dependend on debt financing.
- IDXX has a Debt to Equity ratio (0.53) which is in line with its industry peers.
- Although IDXX does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Altman-Z | 21.68 |
ROIC/WACC4.03
WACC10.01%
2.3 Liquidity
- A Current Ratio of 1.18 indicates that IDXX should not have too much problems paying its short term obligations.
- IDXX has a Current ratio of 1.18. This is amonst the worse of the industry: IDXX underperforms 81.62% of its industry peers.
- IDXX has a Quick Ratio of 1.18. This is a bad value and indicates that IDXX is not financially healthy enough and could expect problems in meeting its short term obligations.
- IDXX's Quick ratio of 0.87 is on the low side compared to the rest of the industry. IDXX is outperformed by 81.08% of its industry peers.
- IDXX does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 |
3. Growth
3.1 Past
- IDXX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.18%, which is quite good.
- Measured over the past years, IDXX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 14.26% on average per year.
- IDXX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.42%.
- Measured over the past years, IDXX shows a quite strong growth in Revenue. The Revenue has been growing by 9.72% on average per year.
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%
3.2 Future
- Based on estimates for the next years, IDXX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.75% on average per year.
- IDXX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.46% yearly.
EPS Next Y13.36%
EPS Next 2Y13.1%
EPS Next 3Y13.3%
EPS Next 5Y13.75%
Revenue Next Year8.92%
Revenue Next 2Y8.91%
Revenue Next 3Y9.16%
Revenue Next 5Y9.46%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 48.26, the valuation of IDXX can be described as expensive.
- Compared to the rest of the industry, the Price/Earnings ratio of IDXX indicates a somewhat cheap valuation: IDXX is cheaper than 69.73% of the companies listed in the same industry.
- When comparing the Price/Earnings ratio of IDXX to the average of the S&P500 Index (27.09), we can say IDXX is valued expensively.
- With a Price/Forward Earnings ratio of 42.57, IDXX can be considered very expensive at the moment.
- 68.65% of the companies in the same industry are more expensive than IDXX, based on the Price/Forward Earnings ratio.
- IDXX is valuated expensively when we compare the Price/Forward Earnings ratio to 27.98, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.26 | ||
| Fwd PE | 42.57 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, IDXX is valued a bit cheaper than the industry average as 67.57% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, IDXX is valued a bit cheaper than the industry average as 72.97% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 53.57 | ||
| EV/EBITDA | 35.04 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IDXX does not grow enough to justify the current Price/Earnings ratio.
- The excellent profitability rating of IDXX may justify a higher PE ratio.
- IDXX's earnings are expected to grow with 13.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.61
PEG (5Y)3.38
EPS Next 2Y13.1%
EPS Next 3Y13.3%
5. Dividend
5.1 Amount
- No dividends for IDXX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
630.73
-4.17 (-0.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-02 2026-02-02/bmo
Earnings (Next)04-29 2026-04-29/bmo
Inst Owners94.94%
Inst Owner Change6.88%
Ins Owners0.21%
Ins Owner Change0.68%
Market Cap50.36B
Revenue(TTM)4.30B
Net Income(TTM)1.03B
Analysts80.91
Price Target781.34 (23.88%)
Short Float %2.29%
Short Ratio3.54
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.14%
Min EPS beat(2)6.47%
Max EPS beat(2)7.81%
EPS beat(4)4
Avg EPS beat(4)5.72%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.83%
EPS beat(12)12
Avg EPS beat(12)4.67%
EPS beat(16)14
Avg EPS beat(16)4.04%
Revenue beat(2)2
Avg Revenue beat(2)1.45%
Min Revenue beat(2)1.03%
Max Revenue beat(2)1.88%
Revenue beat(4)3
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.88%
Revenue beat(8)3
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)-1.06%
Revenue beat(16)4
Avg Revenue beat(16)-1.1%
PT rev (1m)-0.28%
PT rev (3m)12.01%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)0.46%
EPS NY rev (1m)0.19%
EPS NY rev (3m)2.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.37%
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)1.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.26 | ||
| Fwd PE | 42.57 | ||
| P/S | 12.09 | ||
| P/FCF | 53.57 | ||
| P/OCF | 46.29 | ||
| P/B | 32.26 | ||
| P/tB | 48.77 | ||
| EV/EBITDA | 35.04 |
EPS(TTM)13.07
EY2.07%
EPS(NY)14.82
Fwd EY2.35%
FCF(TTM)11.77
FCFY1.87%
OCF(TTM)13.63
OCFY2.16%
SpS52.19
BVpS19.55
TBVpS12.93
PEG (NY)3.61
PEG (5Y)3.38
Graham Number75.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROCE | 61.18% | ||
| ROIC | 40.35% | ||
| ROICexc | 43.87% | ||
| ROICexgc | 56.38% | ||
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% | ||
| FCFM | 22.56% |
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.6%
ROIC(5y)38.02%
ROICexc(3y)42.72%
ROICexc(5y)42.26%
ROICexgc(3y)50.78%
ROICexgc(5y)53.04%
ROCE(3y)53.41%
ROCE(5y)55.15%
ROICexgc growth 3Y-1.85%
ROICexgc growth 5Y-3.56%
ROICexc growth 3Y7.2%
ROICexc growth 5Y1.43%
OM growth 3Y5.66%
OM growth 5Y4.24%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
F-Score8
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Debt/EBITDA | 0.57 | ||
| Cap/Depr | 105.48% | ||
| Cap/Sales | 3.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 75.23% | ||
| Profit Quality | 91.51% | ||
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z | 21.68 |
F-Score8
WACC10.01%
ROIC/WACC4.03
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)3.3%
Cap/Sales(5y)3.67%
Profit Quality(3y)93.71%
Profit Quality(5y)84.62%
High Growth Momentum
Growth
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
EPS Next Y13.36%
EPS Next 2Y13.1%
EPS Next 3Y13.3%
EPS Next 5Y13.75%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%
Revenue Next Year8.92%
Revenue Next 2Y8.91%
Revenue Next 3Y9.16%
Revenue Next 5Y9.46%
EBIT growth 1Y17.46%
EBIT growth 3Y14.66%
EBIT growth 5Y14.37%
EBIT Next Year22.21%
EBIT Next 3Y14.34%
EBIT Next 5Y15.18%
FCF growth 1Y18.62%
FCF growth 3Y40.13%
FCF growth 5Y14.37%
OCF growth 1Y18.68%
OCF growth 3Y29.59%
OCF growth 5Y12.77%
IDEXX LABORATORIES INC / IDXX FAQ
What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IDXX) stock?
ChartMill assigns a fundamental rating of 7 / 10 to IDXX.
What is the valuation status of IDEXX LABORATORIES INC (IDXX) stock?
ChartMill assigns a valuation rating of 4 / 10 to IDEXX LABORATORIES INC (IDXX). This can be considered as Fairly Valued.
Can you provide the profitability details for IDEXX LABORATORIES INC?
IDEXX LABORATORIES INC (IDXX) has a profitability rating of 9 / 10.
What are the PE and PB ratios of IDEXX LABORATORIES INC (IDXX) stock?
The Price/Earnings (PE) ratio for IDEXX LABORATORIES INC (IDXX) is 48.26 and the Price/Book (PB) ratio is 32.26.
What is the expected EPS growth for IDEXX LABORATORIES INC (IDXX) stock?
The Earnings per Share (EPS) of IDEXX LABORATORIES INC (IDXX) is expected to grow by 13.36% in the next year.